ClinicalTrials.gg
CompletedNCT06553209Updated Sep 22, 2025

Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis

A Phase 1 interventional study of CM512 and Placebo in Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd — 4 open to participants now, 5 under way, 3 of them phase 3. Dermatitis, Atopic · Keymed Biosciences Co.Ltd.

Enrollment
13th of 18
110 · median 170
Started
2024
with 2 others
Phase 1
Only one
of the 18
Registered
14th of 18
by date

Among the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, this one is the 13th largest by enrollment, is one of 3 that started in 2024, is the only one in phase 1, and was the 14th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, or all of them as a file.
02

Study summary

This is a randomized, double-blind, single/multiple dose escalation, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in healthy subjects and patients with moderate to severe atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have the ability to understand the study and voluntarily sign a written form (ICF).
  • (BMI) ranges from 18.0 to 26.0 kg/m2 (including boundary values).

Exclusion criteria

Exclusion Criteria:

  • Have participated in any clinical trials of drugs or medical devices within 3 months before the screening.
  • Have severe infections, severe injuries, or undergone major surgical procedures within 3 months before screening.
  • Have lost more than 400 mL of blood due to blood donation or other reasons within 3 months before screening.
  • Positive drug abuse test or positive alcohol breath test result.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Group 1

    Biological: CM512 · Drug: Placebo

  • Experimental
    Group 2

    Biological: CM512 · Drug: Placebo

  • Experimental
    Group 3

    Biological: CM512 · Drug: Placebo

  • Experimental
    Group 4

    Biological: CM512 · Drug: Placebo

  • Experimental
    Group 5

    Biological: CM512 · Drug: Placebo

  • Experimental
    Group 6

    Biological: CM512 · Drug: Placebo

  • Experimental
    Group 7

    Biological: CM512 · Drug: Placebo

Interventions

  • BiologicalCM512

    CM512 injection

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Adverse events

    Incidence of adverse events.

    Time frame: Up to 141 days or up to 169 days

07

Study locations

1 site
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
08

References and documents

Publications

  • Cheng Y, Liu Q, Li M, Xie Y, Men Y, He M, Wang H, Feng X, Zeng M, Zhang L, Chen B, Li J, Feng P. First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. Front Immunol. 2026 May 28;17:1811041. doi: 10.3389/fimmu.2026.1811041. eCollection 2026. PubMed 42292382 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Aug 2025, 11 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 11 months is close to that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2024
First posted
Aug 14, 2024
StartActual
Sep 2, 2024
Primary completionActual
Aug 26, 2025
CompletionActual
Sep 12, 2025
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06553209
Responsible party
Sponsor
First posted
Aug 14, 2024
Start date
Sep 2, 2024
Primary completion
Aug 26, 2025
Completion
Sep 12, 2025
Last update
Sep 22, 2025

Study contacts

Jingyi Li
principal investigator · West China Hospital
Ping Feng
principal investigator · West China Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CM512

Start the discussion